Clinical Factors Predicting Tumour Upgrading in Patients Under Active Surveillance and Elected to Active Treatment after Disease Reclassification or Progression

被引：4

作者：

Porcaro, Antonio Benito ^{[1
]}

Cavicchioli, Francesca ^{[1
]}

De Luyk, Nicolo ^{[1
]}

Mattevi, Daniele ^{[1
]}

Corsi, Paolo ^{[1
]}

Sebben, Marco ^{[1
]}

Tafuri, Alessandro ^{[1
]}

Processali, Tania ^{[1
]}

Inverardi, Davide ^{[1
]}

Cacciamani, Giovanni ^{[1
]}

De Marchi, Davide ^{[1
]}

Balzarro, Matteo ^{[1
]}

Cerruto, Maria A. ^{[1
]}

Brunelli, Matteo ^{[2
]}

Novella, Giovanni ^{[1
]}

Siracusano, Salvatore ^{[1
]}

Artibani, Walter ^{[1
]}

机构：

[1] Azienda Osped Univ Integrata, Osped Policlin, Univ Hosp, Urol Clin, Verona, Italy

[2] Azienda Osped Univ Integrata, Osped Policlin, Univ Hosp, Dept Pathol, Verona, Italy

来源：

UROLOGIA INTERNATIONALIS | 2017年 / 99卷 / 02期

关键词：

Prostate cancer; Low-risk; Active surveillance; Disease progression; Active treatment; Radical prostatectomy; Tumour upgrading; LOCALIZED PROSTATE-CANCER; RADICAL PROSTATECTOMY; GLEASON SCORE; CARCINOMA; BIOPSY; SYSTEM; RISK; MEN;

D O I：

10.1159/000457966

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Objectives: To evaluate clinical factors associated with tumour upgrading (UPG) in low-intermediate risk patients who progressed while under active surveillance (AS) and underwent delayed radical prostatectomy. Material and Methods: The evaluated factors included prostate specific antigen (PSA), prostate volume, PSA density and number of biopsy positive cores (BPC). Multivariate logistic regression by the forward step Wald procedure was used. Results: The study evaluated 24 patients who had UPG in 13 cases (54.2%). Independent factors associated with tumour UPG included PSA (OR 2.1; p = 0.047) and BPC (OR 2; p = 0.042). Conclusions: Clinical factors associated with UPG were identified in patients who were under AS for with low-intermediate risk disease. Preoperative PSA levels and number of BPC were independent factors associated with UPG in a contemporary cohort of patients who progressed under AS and underwent delayed active treatment. (C) 2017 S. Karger AG, Basel

引用

页码：186 / 193

页数：8

共 22 条

[1] Is There a Role for Active Surveillance in Low-Risk Prostate Cancer?
Augustin, Herbert
Mayerhofer, Katrin
Seles, Maximilian
Pummer, Karl
[J]. UROLOGIA INTERNATIONALIS, 2015, 95 (02) : 125 - 131
[2] Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores
Briganti, Alberto
Larcher, Alessandro
Abdollah, Firas
Capitanio, Umberto
Gallina, Andrea
Suardi, Nazareno
Bianchi, Marco
Sun, Maxine
Freschi, Massimo
Salonia, Andrea
Karakiewicz, Pierre I.
Rigatti, Patrizio
Montorsi, Francesco
[J]. EUROPEAN UROLOGY, 2012, 61 (03) : 480 - 487
[3] Active surveillance for prostate cancer: a narrative review of clinical guidelines
Bruinsma, Sophie M.
Bangma, Chris H.
Carroll, Peter R.
Leapman, Michael S.
Rannikko, Antti
Petrides, Neophytos
Weerakoon, Mahesha
Bokhorst, Leonard P.
Roobol, Monique J.
[J]. NATURE REVIEWS UROLOGY, 2016, 13 (03) : 151 - 167
[4] Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients
Caster, Joseph M.
Falchook, Aaron D.
Hendrix, Laura H.
Chen, Ronald C.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 92 (02): : 244 - 251
[5] Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
D'Amico, AV
Whittington, R
Malkowicz, SB
Schultz, D
Blank, K
Broderick, GA
Tomaszewski, JE
Renshaw, AA
Kaplan, I
Beard, CJ
Wein, A
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (11): : 969 - 974
[6] Dahabreh IJ, 2012, ANN INTERN MED, V156, P582, DOI [10.7326/0003-4819-156-8-201204170-00009, 10.7326/0003-4819-156-8-201204170-00397]
[7] The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma
Epstein, JI
Allsbrook, WC
Amin, MB
Egevad, LL
Bastacky, S
Beltrán, AL
Berner, A
Billis, A
Boccon-Gibod, L
Cheng, L
Civantos, F
Cohen, C
Cohen, MB
Datta, M
Davis, C
Delahunt, B
Delprado, W
Eble, JN
Foster, CS
Furusato, M
Gaudin, PB
Grignon, DJ
Humphrey, PA
Iczkowski, KA
Jones, EC
Lucia, S
McCue, PA
Nazeer, T
Oliva, E
Pan, CC
Pizov, G
Reuter, V
Samaratunga, H
Sebo, T
Sesterhenn, I
Shevchuk, M
Srigley, JR
Suzigan, S
Takahashi, H
Tamboli, P
Tan, PH
Têtu, B
Tickoo, S
Tomaszewski, JE
Troncoso, P
Tsuzuki, T
True, LD
van der Kwast, T
Wheeler, TM
Wojno, KJ
[J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (09) : 1228 - 1242
[8] A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score
Epstein, Jonathan I.
Zelefsky, Michael J.
Sjoberg, Daniel D.
Nelson, Joel B.
Egevad, Lars
Magi-Galluzzi, Cristina
Vickers, Andrew J.
Parwani, Anil V.
Reuter, Victor E.
Fine, Samson W.
Eastham, James A.
Wiklund, Peter
Han, Misop
Reddy, Chandana A.
Ciezki, Jay P.
Nyberg, Tommy
Klein, Eric A.
[J]. EUROPEAN UROLOGY, 2016, 69 (03) : 428 - 435
[9] Expectant Management for Men With Early Stage Prostate Cancer
Filson, Christopher P.
Marks, Leonard S.
Litwin, Mark S.
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2015, 65 (04) : 264 - 282
[10] 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C.
Donovan, J. L.
Lane, J. A.
Mason, M.
Metcalfe, C.
Holding, P.
Davis, M.
Peters, T. J.
Turner, E. L.
Martin, R. M.
Oxley, J.
Robinson, M.
Staffurth, J.
Walsh, E.
Bollina, P.
Catto, J.
Doble, A.
Doherty, A.
Gillatt, D.
Kockelbergh, R.
Kynaston, H.
Paul, A.
Powell, P.
Prescott, S.
Rosario, D. J.
Rowe, E.
Neal, D. E.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (15) : 1415 - 1424

← 1 2 3 →